Sheel Biotech Limited (NSE:SHEEL)
India · Delayed Price · Currency is INR 60.00
0.00 (0.00%)
At close: Oct 5, 2026
Sheel Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,100 | 1,018 | 922.82 | 801.16 | 707.36 | |
Revenue Growth | 8.13% | 10.26% | 15.19% | 13.26% | 12.23% |
Cost of Revenue | 694.32 | 657.16 | 576.22 | 541.43 | 478.27 |
Gross Profit | 405.9 | 360.37 | 346.6 | 259.73 | 229.09 |
Selling, General & Admin | 164.28 | 151.99 | 137.99 | 106.37 | 94.22 |
Other Operating Expenses | 32.82 | 58.26 | 63.26 | 65.02 | 70.17 |
Operating Expenses | 207.76 | 219.26 | 211.11 | 181.56 | 173.79 |
Operating Income | 198.14 | 141.11 | 135.49 | 78.17 | 55.3 |
Interest Expense | -14.69 | -14.46 | -11.5 | -11.17 | -9 |
Interest & Investment Income | 2.53 | 0.78 | 0.76 | 0.57 | 3.01 |
Currency Exchange Gain (Loss) | 0.74 | 0.47 | 1.06 | 0.17 | 0.29 |
Other Non Operating Income (Expenses) | -1.26 | -2.68 | -3.29 | -4.04 | -1.08 |
EBT Excluding Unusual Items | 185.46 | 125.22 | 122.52 | 63.7 | 48.53 |
Gain (Loss) on Sale of Assets | -45.3 | 3.01 | - | - | - |
Pretax Income | 140.16 | 128.23 | 122.52 | 63.7 | 48.53 |
Income Tax Expense | 22.6 | 20.68 | 17.78 | 12.93 | -0.04 |
Net Income | 117.56 | 107.55 | 104.75 | 50.77 | 48.57 |
Net Income to Common | 117.56 | 107.55 | 104.75 | 50.77 | 48.57 |
Net Income Growth | 9.31% | 2.68% | 106.34% | 4.52% | 20.48% |
Shares Outstanding (Basic) | 18 | 15 | 15 | 15 | 15 |
Shares Outstanding (Diluted) | 18 | 15 | 15 | 15 | 15 |
Shares Change | 18.94% | 1.86% | - | - | 250.00% |
EPS (Basic) | 6.69 | 7.28 | 7.22 | 3.50 | 3.35 |
EPS (Diluted) | 6.69 | 7.28 | 7.22 | 3.50 | 3.35 |
EPS Growth | -8.10% | 0.83% | 106.29% | 4.51% | -65.58% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -242.28 | 72.76 | -12.14 | 81.38 | 9.81 |
Free Cash Flow Per Share | -13.79 | 4.92 | -0.84 | 5.61 | 0.68 |
Dividend Per Share | - | - | 1.000 | 3.100 | 0.886 |
Dividend Growth | - | - | -67.74% | 250.01% | - |
Gross Margin | 36.89% | 35.42% | 37.56% | 32.42% | 32.39% |
Operating Margin | 18.01% | 13.87% | 14.68% | 9.76% | 7.82% |
Profit Margin | 10.69% | 10.57% | 11.35% | 6.34% | 6.87% |
Free Cash Flow Margin | -22.02% | 7.15% | -1.31% | 10.16% | 1.39% |
EBITDA | 208.8 | 150.11 | 145.36 | 88.34 | 64.7 |
EBITDA Margin | 18.98% | 14.75% | 15.75% | 11.03% | 9.15% |
D&A For EBITDA | 10.66 | 9 | 9.87 | 10.17 | 9.4 |
EBIT | 198.14 | 141.11 | 135.49 | 78.17 | 55.3 |
EBIT Margin | 18.01% | 13.87% | 14.68% | 9.76% | 7.82% |
Effective Tax Rate | 16.12% | 16.13% | 14.51% | 20.30% | - |
Revenue as Reported | 1,107 | 1,023 | 925.46 | 801.94 | 710.66 |
Advertising Expenses | 7.04 | 7.37 | 4.11 | 1.49 | 1.75 |